An­gion's or­gan dam­age drug strikes out again, this time in high-risk kid­ney trans­plant pa­tients

Af­ter flop­ping a test in Covid-19 ear­li­er this year, An­gion’s lead or­gan dam­age drug has now hit the skids again in kid­ney trans­plant pa­tients.

An­gion and part­ner Vi­for Phar­ma’s ANG-3777 failed to beat out place­bo in terms of im­prov­ing eGFR, a mea­sure of kid­ney func­tion, in pa­tients who had re­ceived a de­ceased donor kid­ney trans­plant and were at high risk of de­vel­op­ing what is known as de­layed graft func­tion, ac­cord­ing to Phase III re­sults re­leased Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.